How large is the cardiac troponin market, and what is its growth trajectory?
The cardiac troponin market size has grown rapidly in recent years. It will grow from $3.85 billion in 2024 to $4.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, increasing awareness and early diagnosis of heart conditions, expanding healthcare infrastructure in emerging markets, growth in the elderly population, introduction of high-sensitivity cardiac troponin assays.
The cardiac troponin market size is expected to see rapid growth in the next few years. It will grow to $6.32 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to rising prevalence of lifestyle-related cardiovascular conditions, expansion of cardiac care units in hospitals, increasing adoption of home healthcare, growth in personalized medicine, and demand for more efficient and cost-effective diagnostic solutions. Major trends in the forecast period include adoption of machine learning algorithms for data interpretation in cardiac care, expanding applications of cardiac troponin beyond acute coronary syndrome, advancements in multiplex testing for simultaneous biomarker analysis, development of novel biomarkers alongside troponin, and personalized medicine.
Get Your Free Sample of The Global Cardiac Troponin Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18986&type=smp
What are the key forces behind the cardiac troponin market’s growth in recent years?
The increasing prevalence of heart-related conditions is expected to propel the growth of the cardiac troponin market going forward. Heart-related conditions encompass a range of cardiovascular diseases, including coronary artery disease, heart failure, arrhythmias, and congenital heart defects, affecting the structure and function of the heart. The increasing prevalence of heart-related conditions is driven by factors such as aging populations, sedentary lifestyles, poor dietary habits, and rising rates of obesity and hypertension. Cardiac troponin is crucial in diagnosing heart-related conditions by serving as a highly sensitive biomarker for detecting heart muscle damage, particularly in cases of heart attacks and other cardiac events. For instance, according to the Report on Registration of Births and Deaths 2023 by the Registry of Births and Deaths, Immigration and Checkpoints Authority, Singapore and Ministry Of Health, the total number of deaths attributed to ischemic heart diseases reached 5,302, reflecting a slight increase from 5,290 recorded in 2022. Therefore, the increasing prevalence of heart-related conditions will drive the growth of the cardiac troponin market.
What are the major segments of the cardiac troponin market?
The cardiac troponinmarket covered in this report is segmented –
1) By Type: Troponin I, Troponin T
2) By Location Of Testing: Laboratory Setting, Point Of Care (Poc) Testing
3) By Application: Acute Coronary Syndrome, Myocardial Infraction, Congestive Heart Failure, Other Applications
4) By End User: Hospitals, Diagnostic Centers, Homecare Setting, Other End Users
Subsegments:
1) By Troponin I: Cardiac Troponin I (cTnI), Muscle Troponin I
2) By Troponin T: Cardiac Troponin T (cTnT), Skeletal Troponin T
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cardiac-troponin-global-market-report
Which companies dominate the cardiac troponin market?
Major companies operating in the cardiac troponin market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, Laboratory Corporation of America Holdings (Labcorp), Zoetis Inc., bioMérieux SA, Beckman Coulter Inc., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Radiometer Medical ApS, Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Meso Scale Diagnostics LLC., Singulex Inc., Diazyme Laboratories Inc., Response Biomedical Corporation, Eurolyser Diagnostica GmbH, LifeSign LLC
What major trends will shape the cardiac troponin market during the forecast period?
Major companies operating in the cardiac troponin market are focusing on developing new technology, such as human serum-based quality control, to ensure accurate and reliable high-sensitivity troponin testing by providing multi-analyte controls. Human serum-based quality control in cardiac troponin testing ensures test accuracy and reliability by using human serum with known troponin concentrations to verify the assay’s performance. For instance, in May 2023, Bio-Rad Laboratories, Inc., a US-based biotechnology research company, introduced Cardiac Advance, a four-level, multi-analyte quality control specifically designed for high-sensitivity troponin testing. These liquid, human-serum-based controls are offered in InteliQ 3-mL tubes, Liquichek 3-mL standard, and 2.5-mL compact vials. The controls feature 10 cardiac analytes, including troponin, CK-MB, BNP/proBNP, and myoglobin, and are compatible with Siemens and Roche testing platforms. The products are available in the U.S., Europe, and selected Asian markets.
What are the key regional dynamics of the cardiac troponin market, and which region leads in market share?
North America was the largest region in the cardiac troponin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac troponin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cardiac Troponin Market Report 2025 Offer?
The cardiac troponin market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cardiac troponin refers to a group of proteins found in heart muscle (myocardium) that help regulate heart contractions. Troponins are part of the muscle fiber proteins that control the interaction between actin and myosin, which are essential for muscle contraction. It acts as a biomarkers which is used to diagnose heart injury, especially heart attacks.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18986
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
